Related Experiment Video
Updated: Apr 14, 2026

Intravitreal Injections in the Ovine Eye
Published on: July 5, 2022
Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.
Melissa A Lerman1, Michael D Lewen2, John H Kempen3
1Division of Rheumatology, The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania.
Pediatric uveitis often reactivates after stopping anti-TNFα therapy, with infliximab showing better remission rates than adalimumab. Maintaining treatment longer than 1.5 years did not reduce relapse risk.
Area of Science:
- Ophthalmology
- Rheumatology
- Immunology
Background:
- Pediatric uveitis is a significant cause of vision loss.
- Tumor necrosis factor alpha inhibitors (anti-TNFα) are effective in managing pediatric uveitis.
- Understanding relapse patterns after anti-TNFα treatment is crucial for long-term management.
Purpose of the Study:
- To evaluate the reactivation rates of pediatric uveitis during and after anti-TNFα therapy.
- To identify factors predicting uveitis reactivation in children.
- To compare the long-term outcomes of different anti-TNFα agents.
Main Methods:
- Retrospective cohort study of children (≤18 years) with quiescent uveitis on anti-TNFα.
- Survival analysis to determine reactivation rates on anti-TNFα and after discontinuation.
- Assessment of predictive factors for relapse, including age at onset and specific anti-TNFα agent.
Main Results:
- Approximately 75% of children remained quiescent at 1 year while on anti-TNFα.
- Uveitis reactivation was significantly higher after anti-TNFα discontinuation (63.8%) compared to while on treatment (21.6%).
- Adalimumab use was associated with a higher reactivation risk than infliximab after discontinuation; older age at onset also increased risk.
Conclusions:
- Most children experience uveitis reactivation upon discontinuation of anti-TNFα therapy.
- Infliximab appears to be associated with a higher likelihood of sustained remission off medication compared to adalimumab.
- Extended treatment duration beyond 1.5 years did not appear to decrease the risk of reactivation after discontinuation.
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Cytomegalovirus Disease
Myocarditis III: Medical Management
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

